Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04064294 · ClinicalTrials.gov registry record
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 93
- Enrollment target
NCT04064294: Completed study, sponsored by VA Office of Research and Development.
NCT04064294 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04064294 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 93 participants
- Enrollment target
Study Summary
In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
Primary Outcome
The Unified Dyskinesia Rating Scale (UDysRS) combines patient, caregiver, and treating physician perspectives on both historical (Parts 1 \& 2) and objective (Part 3 \& 4) assessments of dyskinesia and dystonia. The historical portion and the objective ratings are added together to form total score ranging from 0 to 104 with higher scores indicating more severe dyskinesia.
Interventions
- DRUG Intravenous Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2019-08-22 |
| Est. Completion | 2024-03-31 |
What the finished NCT04064294 record still lists
NCT04064294 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Infusion is the first listed.
NCT04064294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04064294 about?
NCT04064294 is a clinical study titled "Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors". In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
What is the current status of trial NCT04064294?
This trial is currently completed. The enrollment target is 93 participants. The study started on 2019-08-22. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT04064294?
The interventions under investigation include: Intravenous Infusion (DRUG).
Who is sponsoring clinical trial NCT04064294?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI